Lack of muscle glycogen phosphorylase activity leads to McArdle's disease, a rare metabolic myopathy. To investigate its molecular basis at the nucleic acid level, we isolated muscle phosphorylase cDNA clones from a human cDNA library in Escherichia coli plasmid pBR 322. Subcloning of one insertion of M13 bacteriophage permitted its definite identification by sequencing. Northern blot experiments revealed one specific messenger RNA of 3.4 kilobases found uniquely in tissues expressing muscle phosphorylase.
Introduction
McArdle's disease is a rare form of metabolic myopathy, genetically transmitted as a recessive autosomal trait.
Clinically, this disease is characterized by asthenia, cramps, stiffness, and attacks of myoglobinuria following physical effort. It is now well established that these manifestations ofthe disorder originate from a depletion in the ATP stores, needed for muscle contraction and relaxation, induced by the absence of glycogen phosphorylase enzyme activity. This enzyme catalyzes the first step of the glycogenolytic pathway that provides most of the readily available energy for intensive muscle contraction. In patients with McArdle's disease, it has been demonstrated by Mommaerts et al. (1) and Schmid and Mahler (2) that glycogen phosphorylase activity is deficient.
In human tissues and those of other mammals, glycogen phosphorylase exists in three isoenzymatic forms: liver, muscle, and brain (3) . The muscle form is the only isoenzyme expressed in skeletal muscle and is also found in heart and brain along Receivedfor publication 7 May 1986 and in revisedform 12 September 1986. with the cerebral form. This explains why the defect in McArdle's disease seems confined to muscle tissue.
The first investigations of the molecular basis of McArdle's disease consisted ofthe search for an inactive protein in patients' muscle. Two kinds of results were obtained: in rare cases, an immunological cross-reacting material was detected in variable amounts (4, 5) , but most patients showed little or no cross-reacting material (CRM)'. This biochemical heterogeneity can be confirmed by direct visualization of the phosphorylase protein with one-(5) or two-dimensional (6) electrophoresis ofthe muscle extracts.
Subsequently, the presence of muscle phosphorylase RNAtranslational activity was investigated in our laboratory in two patients without detectable cross-reacting material and in two heterozygous relatives. It was found that the absence of phosphorylase protein was due to the lack of functional messenger RNA (mRNA) (7) .
Our goal in undertaking the work presented here was to further characterize the molecular basis of McArdle (8) , biochemical (9) , and clinical criteria. All muscle samples were screened for phosphorylase protein by analysis of soluble muscle proteins by denaturing polyacrylamide gel electrophoresis (PAGE) according to Laemmli (10) . cDNA library screening. -8,000 clones of a human muscle cDNA (11) library were screened at low stringency with a 100-basepair (bp) rabbit muscle phosphorylase cDNA probe kindly given by Dr. Putney (Department of Biology, Massachusetts Institute of Technology) (12). Thus we detected three cross-hybridizing cDNA clones (18F1 1; 20ph; 19ph) containing insertions -400, 500, and 1,300 bp long, respectively.
Localization ofthese clones was achieved by partial-restriction enzyme mapping (13) . Two Pst I-Pst I fragments ofthe longer clone 19ph, -600 and 700 bp long, were subcloned in both orientations at the Pst I site of mplO M13 phage ( 14) for use as probes. Subclones of these fragments were sequenced on both strands with the Sanger method of dideoxynucleotide termination (15) . Human aldolase A cDNA clones were obtained and subcloned in Ml 3 phage as described elsewhere (16 Northern blot analysis. RNA samples were equalized to 20 ug/slot by addition of E. coli ribosomal RNA, then run on a vertical methyl mercury hydroxide-1.5% agarose gel. After transfer to nylon filters as described (19) , hybridization was performed for 40 h at 65°C in a 3X standard saline citrate (SSC) solution containing 0.1 % polyvinyl pyrrolidone, 0.1% glycine, 0.1% Ficoll-Hypaque, 10% dextran sulfate, 1% SDS, 10 ,g/ml poly A, 100 jg/ml salmon sperm DNA, plus 1-3 million cpm/ ml of both M13 probes (termed "600" and "700"), with 0.5 ml of hybridization mix per cm' of filter. Final washing was performed in 0.2X SSC + 1% SDS at 650C. Aldolase A mRNA is 1,550 nucleotides long.
Its relative amount is unchanged in various normal muscle samples and McArdle's disease biopsies, as shown by comparison with 28S and 18S ribosomal RNA signals (not shown), obtained by hybridization of filters with a cDNA probe complementary to testis polyA(-)RNA (20) . It thus constituted a useful internal standard for quantification of mRNA. Phosphorylase and aldolase A mRNAs were probed on the same filter that was then autoradiographed overnight at -80°C on AR-XOmat films (Eastman Kodak Co., Rochester, NY) with intensifying screens. Rabbit cDNA (E. coli 23S and 16S, human 28S and 18S ribosomal RNAs). The relative intensity of both bands was measured by densitometric scanning of the autoradiograms with a densitometer (Shimadzu Seisakusho Ltd., Kyoto, Japan).
Southern blot analysis ofgenomic DNA. Total human genomic DNA was prepared from white blood cells as reported (21) . Southern blotting was performed with 2-5 ug of total genomic DNA as described (22 
Results
Restriction mapping permitted location of the three muscle phosphorylase cDNA inserts in relation to the rabbit cDNA insert used for screening. All three insertions covered a COOH terminal region of the phosphorylase cDNA ( Fig. 1) . Identification ofthe cDNA clones by nucleotide sequencing. The longest, most informative clone, (19ph), spans about half the coding region of the cDNA and a short portion of the 3' noncoding region (Fig. 2) . This insertion was subcloned in bacteriophage vector M13. Its sequencing by the Sanger dideoxy technique showed a 94% homology between the deduced amino acid sequence and that of the rabbit protein (23) . Recently, Hwang et al. (24) have characterized a human phosphorylase cDNA clone that overlaps clone l9ph and extends further into the 3' noncoding region, whereas 1 9ph cDNA extends more toward the 5' end (Fig. 1) . Ofthe 1,300 bp we sequenced, we report here a 658-bp region lying upstream of that reported by Hwang et al. (Fig. 2) . Comparing nucleotide sequences of rabbit and human cDNAs, they reported a 90% homology. The same homology can be noted in the overlapping region between the human l9ph and the rabbit cDNA they described (24) . Expression ofmuscle phosphorylase mRNA in different normal human tissues. Northern blot analysis of various adult and fetal human tissues detected a 3.4-kilobase (kb) mRNA species in adult muscle that was not detectable in liver and brain of a 3-mo-old fetus or in adult liver and lung (Fig. 3) . Such a mRNA length is compatible with that expected for a messenger encoding a protein ofabout 841 amino acids, which is the length of rabbit muscle glycogen phosphorylase (23) . This indicates that noncoding sequences consist of -800-900 bp, including the poly A tail.
Protein analysis ofMcArdlepatients. Phosphorylase enzyme activity was undetectable in all 10 patients, and no protein band corresponding to the normal phosphorylase position as seen in controls could be detected by denaturing one-dimensional PAGE (not shown). starting with only 0.5 Mig of total RNA deposited on the gel, i.e., -50 pg of specific RNA.
Next, Northern blots of patients' muscle RNA were hybridized with both phosphorylase and aldolase A probes (Fig. 4) . In five patients (2, 5, 6, 9 , and 10) no specific phosphorylase mRNA could be seen, whereas aldolase A mRNA was present.
In the other three patients, an apparently normal-sized messenger RNA was revealed, but its amount, appreciated from the ratio aldolase signal/phosphorylase signal ( One to three restriction fragments hybridized strongly with the different phosphorylase probes. This permitted, by combining results obtained from the five types of digestion used, the scanning of about 25 kb of DNA, including the C terminal half of the gene. For all individuals studied, restriction patterns were similar in patients and normal controls (4-10 according to the enzyme) (Fig. 5, a and b) . It should be noted that two of these patients were also analyzed by Northern blot. One was found to lack specific mRNA (patient 2); the other exhibited a diminished amount of phosphorylase mRNA (patient 3). Moreover, patient 4 is the son ofheterozygote H2, in which we demonstrated a 50% reduction of muscle phosphorylase mRNA.
Thus, three patients were evaluated, both at the DNA level, where no anomaly was found, and the RNA level with patient 2 and heterozygote H2 corresponding to "nonexpressing alleles" and one, patient 3, corresponding to a "diminished RNA" pattern.
Discussion
By heterologous hybridization with a small rabbit muscle glycogen phosphorylase cDNA probe, we isolated three human glycogen phosphorylase cDNA clones from a human muscle cDNA library.
A firm identification of these clones was obtained by sequencing these insertions, thus determining their position in respect to the known rabbit protein sequence. All three were located in the C terminal half of the mRNA, with the longer insert (I 9ph) covering two fifths of the total messenger and half of the coding sequence.
Comparison ofamino acid sequence deduced from a cDNA sequence of the l9ph insert with the rabbit protein sequence showed a 94% homology between the two protein sequences. Used as probe in Northern blot analysis, the insert recognized a single specific RNA species of 3.4 kb, that was detected only in skeletal muscle, the only tissue among those examined known to express muscle-type glycogen phosphorylase (3) .
In contrast, the probe didn't hybridize in the stringency conditions we used with any brain or liver messenger, thus indicating that it was specific for the muscle isozymes' RNA and did not recognize the brain and liver isozymes' RNA.
Because of the small size and low RNA content of muscle biopsies, we then focused on improving the methods. We first modified classical RNA purification techniques to adapt to small muscle samples. In addition, we used efficient, highly labeled single-stranded cDNA probes copied from subclones in the M 13 vector phage that also permitted easy Southern blot analysis of as little as 2 ,g of genomic DNA.
Purification ofmuscle RNA from small muscle biopsies was made possible by the use of E. coli ribosomal RNA as carrier. The inconvenience of this technique was that it precluded any easy determination of eukaryotic RNA in the obtained preparations and then any direct determination of phosphorylase mRNA from Northern blot analysis. Therefore, we needed to use an internal standard representative ofthe amount of muscle RNA really transferred onto the filters. Aldolase A mRNA appeared to be a convenient standard. Its amount appreciated with respect to total muscle RNA and to the intensity of 28S and 1 8S ribosomal RNA bands hybridized on the blots (20) , relatively constant in different samples of normal deltoid and quadriceps muscles, and the phosphorylase/aldolase ratio in these tissues was identical in each experiment. Although the relative intensity of the phosphorylase and aldolase mRNA bands varied for dif- ferent experiments due to differences in specific and total radioactivity of each probe, phosphorylase mRNA concentration for a given experiment could be correctly evaluated with respect to normal controls blotted on the same filter. It was given by the ratio of phosphorylase band/aldolase band in the patient versus phosphorylase band/aldolase band in the controls. The major fact arising from the investigation of eight unrelated cases with no CRM is that in some patients' muscle no specific glycogen phosphorylase mRNA is detected, whereas in others apparently normal sized mRNA is present, but in diminished amounts. These results contrast with most of the other human genetic diseases presently characterized: citrullinaemia (25), Lesch-Nyhan syndrome (26) , phenylketonuria (27) , Sandhoff's disease (28), Tay-Sachs disease (29) , and adenosine deaminase (30) Therefore it appears that for the four patients whose DNA was studied here, the origin ofthe phosphorylase deficiency could be a point mutation or small deletion (or insertion) in the gene or in its flanking regulatory regions.
In patients (e.g., patient 3 studied here) with apparently normal phosphorylase gene and decreased mRNA concentration the most plausible mechanism is that of a mutation resulting in either the advent of a premature termination codon or abnormal splicing. The latter hypothesis, although not evidenced by a detectable size abnormality of phosphorylase mRNA in patients 3, 7, and 8, cannot be ruled out, as is well illustrated in patients with citrullinemia, in which abnormal arginosuccinate synthetase mRNAs with normal size appear to be frequent (25) . The decrease of the mutant mRNA concentration could arise from instability ofthe messengers carrying an early nonsense mutation due to the occurrence ofa stop codon in an exon or an unspliced intron fragment as already described in different types of thalassemia (33) (34) (35) (36) (37) . In thalassemia it has been proposed that such an instability could result from the absence ofprotection ofRNA by its integration in polysomes (33) . An abnormal splicing could also account for the observations in which DNA is normal in Southern blot analysis whereas mRNA is undetectable (e.g., patient 2 and probably patient 4 in this study). This has been demonstrated in some observations of f3-thalassemia (37) and in analbuminemic rats (38) .
The eventuality of a mutation in the control regions of the phosphorylase gene can be suggested for the patients showing no mRNA at all, but not for cases that exhibit decreased amounts of mRNA. Indeed, if a control region mutation existed in these latter cases, residual mRNA would be structurally and functionally normal and yield a normal active protein. This was not the case.
The definitive elucidation of the genetic lesion involved in the enzyme deficiency will require analysis of residual phosphorylase mRNA, and, at least for the silent alleles, the cloning of the mutant genes and detailed analysis of their nucleotide sequences.
In conclusion, this study demonstrates that in four patients with muscle phosphorylase deficiency, the phosphorylase gene was present and apparently not rearranged. However, a clear heterogeneity was proved at the mRNA level. Phosphorylase mRNA was undetectable in five patients, and in three patients it was present in decreased amounts but with a normal length.
